Q&A

Beyond mRNA Vaccines – Emerging Applications For Lipid Nanoparticle Delivery Technologies

Evonik2

The potential of lipid nanoparticle-based drug delivery technologies to enable a new generation of medicines was made clear to all in 2020.  The first two mRNA vaccines for COVID-19 were rapidly developed and authorized for emergency use after clinical trials demonstrated exceptional levels of efficacy.  But beyond the use of liposomes for small molecule drugs to target systemic diseases such as tumors, and LNPs for vaccines, what other applications are now being explored for such delivery technologies? In this interview, we hear from Dr. Jay Natarajan, Director of R&D, for Evonik’s competence center for LNP technology in Vancouver, Canada.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: